FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare
Related Tags >> Phase III   FDA   Regulators   Drug Trials
Syndicate content

second half News

Most Popular second half Story

Migenix cuts costs to stretch cash

Canada's Migenix is cutting its staff in an effort to preserve cash. The company, which is developing the anti-infective drug Omigard, cut six workers, reduced its CEO's salary and downsized its... Read more...

Latest Headlines